Open AccessEfficacy of I cotinib treatment in patients with stage III b/ IV non‐small cell lung cancer
Author(s) -
Qin Na,
Yang Xinjie,
Zhang Quan,
Li Xi,
Zhang Hui,
Lv Jialin,
Wu Yuhua,
Wang Jinghui,
Zhang Shucai
Publication year - 2014
Publication title -
thoracic cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.823
H-Index - 28
eISSN - 1759-7714
pISSN - 1759-7706
DOI - 10.1111/1759-7714.12085
Subject(s) - medicine , rash , lung cancer , oncology , epidermal growth factor receptor , confidence interval , adverse effect , stage (stratigraphy) , gastroenterology , cancer , paleontology , biology
Background To evaluate the efficacy and safety of I cotinib – an orally administered, highly potent selective inhibitor of epidermal growth factor receptor ( EGFR) and its active mutations, in the treatment of patients with advanced non‐small cell lung cancer ( NSCLC ). Methods A total of 101 patients with stage IIIb / IV NSCLC were treated with 125 mg Icotinib three times a day until disease progression or intolerable toxicity. Response rate was evaluated using response evaluation criteria in solid tumors and progression‐free survival ( PFS) was collected. Results The overall response rate ( ORR ) and disease control rate ( DCR ) were 37.6% (38/101) and 79.2% (80/101), respectively. The median PFS was 6.5 months. Multivariate analysis showed that female gender ( P = 0.048, 95% confidence interval [ CI] 1.010–6.016) and occurrence of rash ( P = 0.002, 95% CI 1.667–9.809) were the independent predictive factors for ORR , while a performance status ( PS) score of 0–1 ( P = 0.001, 95% CI 0.024–0.402) and rash ( P = 0.042, 95% CI 1.089–76.557) were the independent predictive factors for DCR . In addition, PS scores of 0–1 ( P < 0.001, 95% CI 0.135–0.509), and non‐smoking ( P = 0.017, 95% CI 0.342–0.900) were found to be independent influencing factors for PFS . Moreover, patients with EGFR mutations had better PFS than patients with wild type EGFR , while patients with EGFR exon 19 deletion had better survival than those with EGFR exon 21 mutation. The most common adverse effects of Icotinib were rash (35.6%) and diarrhea (17.8%), which was tolerable. Conclusion Treatment of stage IIIb / IV NSCLC patients with Icotinib was effective and tolerable, specifically in patients with EGFR mutation.